The interleukin-23 and T cell type 17 (IL-23/Th17) pathway is recognized as a potential therapeutic target for PV (Ghoreschi et al., 2021; Sharma et al., 2022), with downstream cytokines such as IL-17 and TNF-ɑ being pivotal in the treatment of PV (Bachelez, 2015; Wcislo-Dziadecka et al., 2016). Here, IL17A is linked to acquired polycythemia vera.